SELLAS Life Sciences (SLS) EPS (Weighted Average and Diluted) (2020 - 2024)
SELLAS Life Sciences (SLS) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.08 as the latest value for Q4 2024.
- On a quarterly basis, EPS (Weighted Average and Diluted) rose 65.22% to -$0.08 in Q4 2024 year-over-year; TTM through Dec 2024 was -$0.52, a 61.19% increase, with the full-year FY2024 number at -$0.5, up 62.69% from a year prior.
- EPS (Weighted Average and Diluted) was -$0.08 for Q4 2024 at SELLAS Life Sciences, up from -$0.1 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.08 in Q4 2024 to a low of -$1.05 in Q1 2022.
- A 5-year average of -$0.36 and a median of -$0.33 in 2022 define the central range for EPS (Weighted Average and Diluted).
- Peak YoY movement for EPS (Weighted Average and Diluted): crashed 556.25% in 2022, then soared 69.7% in 2024.
- SELLAS Life Sciences' EPS (Weighted Average and Diluted) stood at -$0.26 in 2020, then crashed by 61.54% to -$0.42 in 2021, then rose by 21.43% to -$0.33 in 2022, then skyrocketed by 30.3% to -$0.23 in 2023, then soared by 65.22% to -$0.08 in 2024.
- Per Business Quant, the three most recent readings for SLS's EPS (Weighted Average and Diluted) are -$0.08 (Q4 2024), -$0.1 (Q3 2024), and -$0.13 (Q2 2024).